Navigation Links
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Date:5/21/2009

SAN FRANCISCO, May 21 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that additional clinical results from a Phase 1-2 clinical trial involving 140 men with advanced prostate cancer evaluating MDV3100, a next-generation androgen receptor antagonist, will be presented in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.

    Oral Abstract Session:      Genitourinary (Prostate) Cancer

    Abstract Title:            "Antitumor Activity of MDV3100 in a Phase 1-2
                               Study of Castration-Resistant Prostate Cancer
                               (CRPC)" (Abstract #5011)

    Presentation Date/Time:     Saturday, May 30, at 4:15 p.m. ET

    Presenter:                  Dr. Howard Scher, principal investigator,
                                chief of the Genitourinary Oncology Service
                                and the D. Wayne Calloway Chair in Urologic
                                Oncology at Memorial Sloan-Kettering Cancer
                                Center in New York

    Location:                   Level 3, Chapin Theater W320

Additionally, this abstract was selected by ASCO for inclusion in the Best of ASCO(R) program, an educational initiative covering highlights from the ASCO Annual Meeting to increase global access to cutting-edge science.

Medivation recently received written permission from the U.S. Food and Drug Administration to begin a pivotal Phase 3 trial of MDV3100 in patients with advanced prostate cancer. The primary endpoint of the trial will be overall survival.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the U
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , ... August 03, 2015 , ... Sutter Health’s California ... operating officer (COO) at CPMC. Hamila will start in her role effective immediately and ... , Kownacki has worked at CPMC and Sutter Health for about 15 years, including ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic ... health IT to create efficiencies in healthcare information exchange, announced the release of its ... Health and Human Services (HHS) Secretary, WEDI shared survey results and ...
(Date:8/3/2015)... ... 03, 2015 , ... Kantor & Kantor, LLP announced today ... client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement Income ... treatment for bulimia, depression and other mental health problems. , According to the ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Health notes that while an overwhelming number of Hispanics believe people can ... The overwhelming 70 percent of participants queried said making diet changes was important. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... its industry-defining contract lifecycle management solution, as well as announced the date of ... the speed and ease of contract management tasks as well as enhancements to ...
Breaking Medicine News(10 mins):Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2
... Feb. 6 MaxCyte, Inc., a,clinical-stage therapeutics company ... Douglas Doerfler, President & CEO, will be,presenting at ... York,Waldorf=Astoria, on Monday, February 11, 2008 at 11:45AM., ... overview and discuss the,company,s preclinical and clinical product ...
... of nevirapine greatly reduced infant infections in Africa, ... News) -- The antiretroviral drug nevirapine greatly reduces ... virus to their babies during breast-feeding, according to ... Nevirapine is already in widespread use in developing ...
... Introduces World,s First Collaborative Platform to Integrate, ... WAYLAND, Mass., Feb. 6 Tourtellotte ... for the bio-pharmaceutical industry, is,pleased to announce ... document,management and collaboration platform for complex document ...
... Inc. (Amex:,UPI), a medical device company that develops, ... of voiding dysfunction,announced today that it will be ... on Wednesday, February 20, 2008 at the Ritz ... and Medi Jiwani,Uroplasty,s Vice President and CFO, will ...
... PHILADELPHIA, Feb. 6 The much,anticipated launch ... eToims(R),Soft Tissue Comfort Center, LLC, a University ... Intramuscular,Stimulation (eToims(R) Twitch Relief Method). The site ... including back pain (the second most,common neurological ...
... well as standard, invasive method , , TUESDAY, Feb. 5 (HealthDay ... cancer has spread may be better than traditional, invasive procedures. ... of the Journal of the American Medical Association , ... era for people with lung cancer or suspected lung cancer. ...
Cached Medicine News:Health News:Drug Helps Prevent Breast-Feeding Moms From Passing on HIV 2Health News:Tourtellotte Solutions' Fusion DMC(TM) Unifies the World of Bio-Pharma Documents 2Health News:StopMusclePain.com Launched as Only Website Dedicated to Reversing Back Pain 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 3
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") announcement ... Directors ("Depomed Board") set a record date to determine ... The Depomed Board will review the request ... received today and contains the information required under Depomed,s ...
(Date:8/3/2015)... According to a new ... Market Study on Physiotherapy Equipment - ... 2022", the global physiotherapy equipment market is estimated to be ... and is expected to grow at a CAGR ... for US$23.7 Bn by 2022. View Full ...
(Date:8/3/2015)... , August 3, 2015 ... biotech companies, military surgical research and top-tier ... with regards to severe wound treatments for ... for regenerative medicine and tissue-engineered skin substitute ... and advancements in focus are Amarantus Bioscience ...
Breaking Medicine Technology:Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... is a lateral-flow immuno-chromatographic assay intended for ... specific to Helicobacter pylori in human serum, ... convenient, non-invasive, and easy to perform test ... of H.pylori infection in patients with clinical ...
... HP is a visually read, qualitative immunochromatographic ... H. pylori, a bacterium that grows in ... ulcer disease and some gastric cancers. FlexSure ... blood or serum samples, provides the physician ...
... Infectious Mononucleosis test is designed to ... serum, plasma or whole blood. The ... extract of bovine erythrocytes which give ... similar extracts prepared from sheep and ...
... The QuickVue Influenza A+B test ... of influenza type A and type ... nasal wash and/or nasal aspirate specimens. ... aid in the rapid differential diagnosis ...
Medicine Products: